NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...
Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com ...
DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...
8d
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be ...
In a recent transaction, Justin B. Klee, Co-Chief Executive Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), sold 11,855 shares of common stock. The company, currently valued at $246 million, ...
Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...
Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback